Next Article in Journal
The Prevalence of Helicobacter pylori in Estonian Bariatric Surgery Patients
Next Article in Special Issue
Polymeric Nano-Micelles as Novel Cargo-Carriers for LY2157299 Liver Cancer Cells Delivery
Previous Article in Journal
An in Vitro Study on the Effect of Combined Treatment with Photodynamic and Chemical Therapies on Candida albicans
Previous Article in Special Issue
Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(2), 255;

Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies

Dipartimento di Scienze della Salute, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy
Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10124 Torino, Italy
Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Largo Paolo Braccini 2, 10095 Grugliasco (TO), Italy
Centro di Neuro Bio Oncologia, Policlinico di Monza, Via Pietro Micca 5, 13100 Vercelli, Italy
Author to whom correspondence should be addressed.
Received: 20 December 2017 / Revised: 11 January 2018 / Accepted: 18 January 2018 / Published: 24 January 2018
(This article belongs to the Special Issue Nanotechnology in Drug Delivery)
Full-Text   |   PDF [8673 KB, uploaded 24 January 2018]   |  


Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies. View Full-Text
Keywords: SLN; melanoma; temozolomide SLN; melanoma; temozolomide

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Clemente, N.; Ferrara, B.; Gigliotti, C.L.; Boggio, E.; Capucchio, M.T.; Biasibetti, E.; Schiffer, D.; Mellai, M.; Annovazzi, L.; Cangemi, L.; Muntoni, E.; Miglio, G.; Dianzani, U.; Battaglia, L.; Dianzani, C. Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. Int. J. Mol. Sci. 2018, 19, 255.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top